Glenmark Pharmaceuticals Receives US FDA Approval for Generic Fluticasone Nasal Spray
Glenmark Pharmaceuticals received US FDA approval for its generic Fluticasone Propionate Nasal Spray USP, 0.05 mg, bioequivalent to Flonase Nasal Spray. The product will be distributed in the US by Glenmark Pharmaceuticals Inc., USA. The Flonase market recorded annual sales of about USD 295.2 million for the 12 months ending June 2026. Glenmark recently reported strong financial results, including a significant rise in quarterly and annual profits, driven by growth in specialty medicines and respiratory therapies.
First-hand measurement across 6 sources
We measured how 6 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (64/100). Lens Score 38/100.
Outlets measured: businessstandard, businessstandard, news18, moneycontrol, businessstandard, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 19 Aug, 09:20 am. Other outlets followed.